Allogene Therapeutics, Inc. (ALLO)
0.8075
-0.03
(-3.72%)
USD |
NASDAQ |
Nov 16, 16:00
0.8075
0.00 (0.00%)
After-Hours: 19:05
Allogene Therapeutics Enterprise Value : 74.40M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 74.40M |
| November 12, 2026 | 70.35M |
| November 11, 2026 | 95.66M |
| November 10, 2026 | 106.68M |
| November 09, 2026 | 151.03M |
| November 06, 2026 | 144.11M |
| November 05, 2026 | 161.42M |
| November 04, 2026 | 196.05M |
| November 03, 2026 | 171.81M |
| November 02, 2026 | 161.42M |
| October 30, 2026 | 192.59M |
| October 29, 2026 | 216.83M |
| October 28, 2026 | 234.14M |
| October 27, 2026 | 209.90M |
| October 26, 2026 | 202.98M |
| October 23, 2026 | 216.83M |
| October 22, 2026 | 216.83M |
| October 21, 2026 | 244.53M |
| October 20, 2026 | 244.53M |
| October 19, 2026 | 234.14M |
| October 16, 2026 | 237.60M |
| October 15, 2026 | 247.99M |
| October 14, 2026 | 234.14M |
| October 13, 2026 | 230.68M |
| October 12, 2026 | 268.77M |
| Date | Value |
|---|---|
| October 09, 2026 | 289.55M |
| October 08, 2026 | 268.77M |
| October 07, 2026 | 279.16M |
| October 06, 2026 | 289.55M |
| October 05, 2026 | 303.40M |
| October 02, 2026 | 303.40M |
| October 01, 2026 | 317.25M |
| September 30, 2026 | 338.03M |
| September 29, 2026 | 305.86M |
| September 28, 2026 | 309.32M |
| September 25, 2026 | 316.22M |
| September 24, 2026 | 323.13M |
| September 23, 2026 | 323.13M |
| September 22, 2026 | 336.95M |
| September 21, 2026 | 330.04M |
| September 18, 2026 | 330.04M |
| September 17, 2026 | 343.85M |
| September 16, 2026 | 330.04M |
| September 15, 2026 | 340.40M |
| September 14, 2026 | 361.12M |
| September 11, 2026 | 361.12M |
| September 10, 2026 | 354.21M |
| September 09, 2026 | 343.85M |
| September 08, 2026 | 388.75M |
| September 04, 2026 | 426.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oncolytics Biotech, Inc. | 46.90M |
| Sangamo Therapeutics, Inc. | 40.22M |
| Sarepta Therapeutics, Inc. | 1.897B |
| Anixa Biosciences, Inc. | 75.65M |
| Vicapsys Life Sciences, Inc. | 16.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.37M |
| Total Expenses (Quarterly) | 50.37M |
| EPS Diluted (Quarterly) | -0.1455 |
| Earnings Yield | -77.30% |
| Normalized Earnings Yield | -77.31 |